Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Head & Neck 1Dermatologic 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Noonan Syndrome 1Melanoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × nazartinib × Dermatologic × Clear all
NCT03114319 2026-04-16

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Novartis

Phase 1 Terminated
227 enrolled
DermatologicGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Melanoma, Noonan Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡